<SEC-DOCUMENT>0001104659-20-091418.txt : 20200806
<SEC-HEADER>0001104659-20-091418.hdr.sgml : 20200806
<ACCEPTANCE-DATETIME>20200806160530
ACCESSION NUMBER:		0001104659-20-091418
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20200806
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200806
DATE AS OF CHANGE:		20200806

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			APPLIED DNA SCIENCES INC
		CENTRAL INDEX KEY:			0000744452
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISCELLANEOUS BUSINESS SERVICES [7380]
		IRS NUMBER:				592262718
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36745
		FILM NUMBER:		201081542

	BUSINESS ADDRESS:	
		STREET 1:		50 HEALTH SCIENCES DRIVE
		CITY:			STONY BROOK
		STATE:			NY
		ZIP:			11790
		BUSINESS PHONE:		631-240-8800

	MAIL ADDRESS:	
		STREET 1:		50 HEALTH SCIENCES DRIVE
		CITY:			STONY BROOK
		STATE:			NY
		ZIP:			11790

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PROHEALTH MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	20010504

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DCC ACQUISITION CORP
		DATE OF NAME CHANGE:	19990211

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DATALINK CAPITAL CORP/TX/
		DATE OF NAME CHANGE:	19980306
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2020564d3_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="border-top: Black 2pt solid; font-size: 1pt; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B>&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="text-align: center; margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="text-align: center; border-top: black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(d) OF THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="text-align: center; margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="text-align: center; border-top: black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of Report (Date of earliest event
reported): August 6, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Applied DNA Sciences, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant as specified
in its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; width: 33%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Delaware</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(State or other jurisdiction<BR>
        of incorporation)</P></TD>
    <TD STYLE="text-align: center; width: 34%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>001-36745</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Commission File Number)</P></TD>
    <TD STYLE="text-align: center; width: 33%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>59-2262718</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(IRS Employer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Identification No.)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>50 Health Sciences Drive</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Stony Brook, New York 11790</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive offices;
zip code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Registrant&rsquo;s telephone number, including
area code: <B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>631-240-8800</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>N/A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.95pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><FONT STYLE="background-color: white">Securities
registered pursuant to Section 12(b) of the Act:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; width: 38%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title
    of each class</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center"></TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Trading&nbsp;Symbol(s)</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center"></TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 38%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name
    of each exchange on which registered</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-top: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock, $0.001
    par value</FONT></TD>
    <TD STYLE="padding-top: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-top: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">APDN</FONT></TD>
    <TD STYLE="padding-top: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-top: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Nasdaq Capital
    Market</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter). Emerging growth company&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 2.02&nbsp;Results of Operations and Financial Condition.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">On August 6, 2020, Applied DNA Sciences, Inc. (the &ldquo;Company&rdquo;)
issued a press release announcing its results of operations for the fiscal third quarter ended June 30, 2020. A copy of the press
release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">The information furnished pursuant to this Item 2.02, including
Exhibit 99.1, shall not be deemed &ldquo;filed&rdquo; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended
(the &ldquo;Exchange Act&rdquo;), or otherwise subject to the liabilities under that Section and will not be deemed to be incorporated
by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as will
be expressly set forth by specific reference in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01.&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(<I>d) Exhibits</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Exhibit No.</U></B></FONT></TD>
    <TD STYLE="width: 0.1in">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Description</U></B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt"><A HREF="tm2020564d3_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="padding-top: 3pt">&nbsp;</TD>
    <TD STYLE="padding-top: 3pt; text-align: justify"><A HREF="tm2020564d3_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release of Applied DNA Sciences, Inc. dated August 6, 2020 regarding results of operations for the fiscal third quarter ended June 30, 2020.</FONT></A></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: August 6,
    2020</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">APPLIED
    DNA SCIENCES, INC.</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 27%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 20%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/&nbsp;James&nbsp;A.&nbsp;Hayward</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James A. Hayward</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive
    Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2020564d3_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: right"><B><IMG SRC="image_001.jpg" ALT=""></B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Applied DNA Reports
Fiscal Third Quarter 2020 Financial Results</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: center"><I>Company to Hold Conference Call and Webcast
Today,<BR>
Thursday, August 6, 2020, at 4:30 PM EDT</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #0A0A0A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: #0A0A0A"><B>STONY BROOK, N.Y.</B> &ndash; August 6, 2020
- Applied DNA Sciences, Inc. (NASDAQ: APDN) (&ldquo;Applied DNA&rdquo; or the &quot;Company&quot;), a leader in Polymerase Chain
Reaction (PCR)-based DNA manufacturing that enables <I>in vitro</I> diagnostics, pre-clinical nucleic acid-based therapeutic drug
candidates, supply chain security, anti-counterfeiting and anti-theft technology, today announced consolidated financial results
for the fiscal third quarter and the nine months ended June 30, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: #0A0A0A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: #0A0A0A">&ldquo;We continued during the quarter to position
the Company to serve the unmet and evolving needs for COVID-19 testing solutions and vaccine development,&rdquo; said Dr. James
A. Hayward, president and CEO of Applied DNA Sciences. &ldquo;Upon the receipt of FDA Emergency Use Authorization (&ldquo;EUA&rdquo;)
for our Linea&trade; COVID-19 diagnostic assay kit (for use with nasopharyngeal (NP) swab and anterior nasal swab (ANS) sample
collections), we put into place the foundation of our COVID-19 diagnostics business: we established the requisite supply chains
and inventory to support anticipated growth in assay kit demand; we formed a clinical lab subsidiary (Applied DNA Clinical Labs
LLC) that, once certified by the State of New York, will offer testing as a service (&ldquo;TaaS&rdquo;) whose potential economics
to us is more favorable than that of standalone kit sales; and we applied for amendments to our EUA to expand the addressable market
for our kits and improve customer testing turnaround time and throughput. We are in the marketplace today with what we believe
to be a highly sensitive and purpose-designed platform for the high-throughput workflows found at clinical diagnostic laboratories
nationally. We are currently pursuing diagnostic kit contracts and, upon State certification, commercial testing contracts.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: #0A0A0A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: #0A0A0A">Continued Dr. Hayward, &ldquo;The U.S. is facing
bottlenecks in testing capacity with supply shortages and testing backlogs at laboratories that, together with the spike in infection
numbers in the southern and western parts of the country, suggests greater and long-term demand for testing. We believe we are
well-positioned to deliver greater patient access to testing and increased market penetration in the coming quarters. The recent
amendments to our EUA advance our go-to-market strategy significantly: they greatly enhance our opportunity for commercial kit
sales by increasing the size of the installed base of RT-PCR systems upon which our kit can run and they enable the use of automated
RNA extraction robotics at third-party labs and at Applied DNA Clinical Labs LLC, when licensed, to increase testing throughput.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: #0A0A0A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: #0A0A0A">&ldquo;We have also recruited our first research
sponsors who have funded the development of pooling models for the testing of asymptomatic patients (screening testing), which
we will be presenting to FDA. We believe that our ability to sample for the virus using the less-invasive ANS will enhance compliance
among students and asymptomatic individuals who may require multiple rounds of testing. Several academic institutions are contemplating
COVID-19 safety programs based upon the use of our diagnostic kit to enhance the safety of students, faculty, and staff. We have
recruited both internal and external sales infrastructures to drive demand for our diagnostic kit.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: #0A0A0A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: #0A0A0A">Commenting on the development of the Company&rsquo;s
vaccine candidates co-developed with Takis S.R.L. and Evvivax S.R.L. (collectively, &ldquo;Takis Biotech&rdquo;), Dr. Hayward stated,
&ldquo;Tests on the linear DNA&trade; forms of our COVID-19 vaccine candidates provoked seroconversion in mouse models that are
consistent with prior data from the plasmid forms of the vaccine candidates by Takis Biotech. Our results suggest that a low-dose
vaccine could be potentially effective in providing protection while the T cell response suggests potential long-term persistence.
We believe our results in animal models echo the effectiveness announced by some of the COVID-19 vaccines already in human trials.
We have attracted the attention of &lsquo;Big Pharma&rsquo; and are presently negotiating rights to novel delivery systems and
funding for sophisticated toxicology screens done in collaboration with our partner Takis Biotech and their network of service
partners.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: #0A0A0A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: #0A0A0A">With regard to the Company&rsquo;s non-biological
business segment, Dr. Hayward said, &ldquo;Our supply chain security segment felt the full brunt of COVID-19 in the fiscal third
quarter that resulted in a further weakening of demand for tagging and related services across the global supply chain chains we
serve. We remain focused on business-building in key industrial and regulated markets, including textiles, cannabis, personal care,
nutraceuticals, and pharmaceuticals, ahead of the return of increased demand patterns.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: #0A0A0A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: #0A0A0A">Concluded Dr. Hayward, &ldquo;Looking ahead,
we are focused on advancing our COVID-19 diagnostic kit and TaaS market strategy and progressing the development of the linear
DNA&trade; forms of our vaccine candidates. To drive broader adoption of our kit by laboratories and to increase TaaS opportunities,
we plan additional EUA amendments to further expand the base of RT-PCR systems relevant to our kit and to secure the ability to
conduct asymptomatic screening testing, which we believe would confer onto us a potentially significant commercial advantage in
the marketplace. We also await New York State certification of Applied DNA Clinical Labs LLC that would initiate commercial testing
revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: #0A0A0A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: #0A0A0A"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: #0A0A0A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: #0A0A0A">&ldquo;In
the development of our vaccine candidates, we expect to launch of toxicology screens once funding is secured followed by higher
animal studies before initiating human trials. We are recruiting industry partners to lead on the regulatory process and distribution
with Applied DNA serving as the sole-source manufacturer globally. With our linear DNA<SUP>TM</SUP> manufacturing platform, we
are differentiated not only for our ability to manufacture any linear DNA&trade; form of a COVID-19 vaccine at extremely large
scale, but also for our ability to react to any new variants of the virus with unrivaled speed.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: #0A0A0A">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: #0A0A0A"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: #0A0A0A"><B><U>Recent Business Highlights:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: #0A0A0A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: #0A0A0A"><B>COVID-19</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 6pt; color: #0A0A0A"><B><I>Linea<SUP>TM</SUP>&nbsp;COVID-19 SARS-CoV-2
Assay Kit</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #0A0A0A">On July 31, 2020, the Company
announced that the U.S. Food and Drug Administration (FDA) had granted its second EUA amendment that increases the size of the
installed base of RT-PCR systems upon which the Company&rsquo;s diagnostic assay kit can run as well as the speed and throughput
of the laboratory process, including RNA extraction, via a robotic platform. The EUA was granted to Applied DNA on May 13, 2020,
and the first amendment to the EUA was granted on July 8, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #0A0A0A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: #0A0A0A">The second
amendment to the EUA: 1) extends the RT-PCR platform from the Applied Biosystems (ThermoFisher Scientific) QuantStudio&trade; Dx&nbsp;to
include Applied Biosystems&rsquo; QuantStudio&trade; 5 Real-Time PCR system to analyze patient samples on the company&rsquo;s Linea&trade;
COVID-19 assay kit; and 2) authorized the use of the Hamilton STARlet robotic automation in conjunction with the</FONT> Omega Bio-tek
MagBind&reg; viral RNA Express kit to speed the process of extracting viral RNA from specimens and drive greater testing throughput.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: #0A0A0A">The
scope of the EUA, as amended, is expressly limited to use consistent with the Instructions for Use by authorized laboratories,
certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) to perform high complexity tests. The EUA will be
effective until the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostics
for detection and/or diagnosis of COVID-19 is terminated or until the EUA&rsquo;s prior termination or revocation. The diagnostic
kit has not been FDA cleared or approved, and the EUA&rsquo;s limited authorization is only for the detection of nucleic acid from
SARS-CoV-2, not for any other viruses or pathogens.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 6pt; color: #0A0A0A"><B><I>Vaccine Candidates</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #0A0A0A">On July 17, 2020, Applied
DNA and its vaccine development partner, Takis Biotech, announced that linear DNA&trade; forms of COVID-19 vaccine candidates under
development by Takis Biotech and manufactured by the Company yielded strong antibody and T-cell responses even at very low doses
of linear DNA&trade;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #0A0A0A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #0A0A0A">The Company believes that
linear DNA&trade; vaccines offer a broad array of potential advantages: stability during storage and shipment, the capacity to
manufacture both centrally and locally across the globe, vaccine expression without apparent integration into the patient&rsquo;s
genome, the avoidance of antibiotics, no risk of transference of antibiotic-resistance genes, the avoidance of bacterial vectors,
high purity and simplicity of production, and apparent high efficacy. Given the mutational proclivity of SARS-CoV-2, and the synthetic
genomic design skills of Takis Biotech, the Company believes it could manufacture an improved linear DNA&trade; vaccine within
weeks of obtaining the sequence of a mutant variant that dodged any future vaccines targeting then dominant variants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: #0A0A0A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 6pt; color: #0A0A0A"><B><I>Applied DNA Clinical Labs LLC (&ldquo;ADCL&rdquo;)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: #0A0A0A">On July 9, 2020, the Company announced the formation
of ADCL as a wholly-owned subsidiary dedicated to the commercial development of its tests in virology (for the detection of COVID-19)
and in oncology (for the detection and enumeration of invasive Circulating Tumor Cells (iCTCs) in patients with cancer).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: #0A0A0A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: #0A0A0A">In forming ADCL, Applied DNA is executing on
a strategy to expand its market reach through value-added services complementary to a growing portfolio of diagnostic assays attractive
to a broader number of qualified labs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: #0A0A0A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 6pt; color: #0A0A0A"><B>Corporate </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: #0A0A0A">On June 26, 2020, the Company announced that
it had joined the Russell Microcap&reg;&nbsp;Index (the &ldquo;Index&rdquo;) following the conclusion of the 2020 Russell indexes
annual reconstitution.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: #0A0A0A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #0A0A0A"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #0A0A0A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #0A0A0A"><B>Fiscal Third Quarter 2020 Financial Results:</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; color: #0A0A0A; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="padding-top: 6pt; width: 0.25in"></TD><TD STYLE="padding-top: 6pt; width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-top: 6pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Revenues
decreased 79% for the third quarter of fiscal 2020 to $432 thousand, compared with $2.1 million reported in the third quarter
of fiscal 2019, and decreased 22% from the $552 thousand reported in the second fiscal quarter ended March 31, 2020. The decrease
in year-over-year revenues was due primarily to a decrease in revenue from a licensing agreement in the cannabis industry of $1.0
million, as well as cannabis feasibility pilots of $137 thousand during the three months ended June 30, 2019. The decrease also
relates to a decline in revenues of approximately $213 thousand from the government development contract award that expired during
the second half of fiscal 2019. The remaining decrease related to a decline in product revenue as a result of lower textile and
biopharmaceutical revenue.</FONT></TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="padding-top: 3pt; width: 0.25in"></TD><TD STYLE="padding-top: 3pt; width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-top: 3pt; text-align: justify">Total operating expenses increased to $3.5 million
for the third fiscal quarter of 2020, compared with $3.2 million in the prior fiscal year&rsquo;s third quarter. This increase
is primarily attributable to an increase in selling, general and administrative expenses of $182 thousand. This increase was the
result of stock-based compensation expense. There was also an increase of approximately $95 thousand in research and development
expenses, specifically as it relates to the development of our Linea COVID-19 diagnostic assay kit.</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="padding-top: 3pt; width: 0.25in"></TD><TD STYLE="padding-top: 3pt; width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-top: 3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
loss for the quarter ended June 30, 2020 was $3.3 million, or $0.72 per share, compared with a net loss of $1.5 million, or $1.55
per share, for the quarter ended June 30, 2019, and a net loss of $3.0 million, or $0.79 per share, for the quarter ended March
31, 2020.</FONT></TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="padding-top: 3pt; width: 0.25in"></TD><TD STYLE="padding-top: 3pt; width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-top: 3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #0A0A0A">Excluding
non-cash expenses, Adjusted EBITDA was negative $2.8 million and a negative $1.2 million for the quarters ended June 30, 2020
and 2019, respectively. See below for information regarding non-GAAP measures.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #0A0A0A"><B>Nine-Month Financial Highlights:</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; color: #0A0A0A; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="padding-top: 6pt; width: 0.25in"></TD><TD STYLE="padding-top: 6pt; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify; padding-top: 6pt"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; color: #0A0A0A">Revenues for the first nine months of fiscal
2020 totaled $1.6 million, a decrease of 56% from $3.7 million from the same period in the prior fiscal year.&nbsp;The decrease
in revenues was due to a decline in revenue of approximately $613 thousand associated with the completion of a government contract
award, which was completed during the second half of fiscal 2019, as well as decreases of approximately $1.2 million in cannabis
due to a decline in licensing and feasibility projects year over year.</P></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-top: 3pt"></TD><TD STYLE="padding-top: 3pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify; padding-top: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Operating expenses for the nine months ended June 30, 2020 decreased
by $886 thousand or 9% for the same period last fiscal year. The decrease is primarily attributable to a decrease in stock-based
compensation, consulting, travel and legal and professional fees, as well as a decrease in payroll of $273 thousand. </FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-top: 3pt"></TD><TD STYLE="padding-top: 3pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify; padding-top: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net loss for the nine months ended June 30, 2020 was $8.9 million
or $2.54 per share, compared with a net loss of $7.4 million or $8.46 per share for the nine months ended June 30, 2019.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-top: 3pt"></TD><TD STYLE="padding-top: 3pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify; padding-top: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Excluding non-cash expenses and interest, Adjusted EBITDA for the
nine months ended June 30, 2020 was a negative $7.8 million as compared to a negative $6.1 million for the same period in the prior
fiscal year. See below for information regarding non-GAAP measures.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 6pt; color: #0A0A0A"><B>Fiscal Third Quarter 2020 Conference Call
Information</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company will hold a conference call and webcast to discuss
its fiscal third quarter-end 2020 results on Thursday, August 6, 2020 at 4:30 PM ET. To participate on the conference call, please
follow the instructions below. While every attempt will be made to answer investors&rsquo; questions on the Q&amp;A portion of
the call, due to the large number of expected participants, not all questions may be answered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>To Participate: </B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; color: #0A0A0A; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="padding-top: 6pt; width: 0.25in"></TD><TD STYLE="padding-top: 6pt; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify; padding-top: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Participant Toll Free:1-844-887-9402</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-top: 3pt"></TD><TD STYLE="padding-top: 3pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify; padding-top: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Participant Toll: 1-412-317-6798</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-top: 3pt"></TD><TD STYLE="padding-top: 3pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify; padding-top: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Please ask to be joined to the Applied DNA Sciences call</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Live webcast: <FONT STYLE="color: Blue"><U>https://services.choruscall.com/links/apdn200806.html</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Replay (available 1 hour following
the conclusion of the live call through August 3, 2020):</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; color: #0A0A0A; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="padding-top: 6pt; width: 0.25in"></TD><TD STYLE="padding-top: 6pt; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify; padding-top: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Participant Toll Free: 1-877-344-7529</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-top: 3pt"></TD><TD STYLE="padding-top: 3pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify; padding-top: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Participant Toll: 1-412-317-0088</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-top: 3pt"></TD><TD STYLE="padding-top: 3pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify; padding-top: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Participant Passcode: 10146786</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Webcast replay: <FONT STYLE="color: Blue"><U>https://services.choruscall.com/links/apdn200806.html</U></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For those investors unable to attend the live call, a copy
of management&rsquo;s PowerPoint presentation will be available for review under &lsquo;IR Calendar&rsquo; portion of the Company&rsquo;s
Investors web site: <FONT STYLE="color: Blue"><U>https://adnas.com/molecular-based-security/investors/</U></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Information about Non-GAAP Financial Measures</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As used herein, &ldquo;GAAP&rdquo; refers to accounting principles
generally accepted in the United States of America. To supplement our condensed consolidated financial statements prepared and
presented in accordance with GAAP, this earnings release includes Adjusted EBITDA, which is a non-GAAP financial measure as defined
in Rule 101 of Regulation G promulgated by the Securities and Exchange Commission. Generally, a non-GAAP financial measure is a
numerical measure of a company&rsquo;s historical or future performance, financial position, or cash flows that either excludes
or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented
in accordance with GAAP. The presentation of this non-GAAP financial information is not intended to be considered in isolation
or as a substitute for, or superior to, the financial information presented in accordance with GAAP. We use this non-GAAP financial
measure for internal financial and operational decision-making purposes and as a means to evaluate period-to-period comparisons
of the performance and results of operations of our core business. Our management believes that these non-GAAP financial measures
provide meaningful supplemental information regarding the performance of our business by excluding non-cash expenses that may not
be indicative of our recurring operating results. We believe this non-GAAP financial measure is useful to investors as they allow
for greater transparency with respect to key metrics used by management in its financial and operational decision making.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&ldquo;EBITDA&rdquo;- is defined as earnings (loss)
before interest expense, income tax expense and depreciation and amortization expense.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&ldquo;Adjusted EBITDA&rdquo;-
is defined as EBITDA adjusted to exclude (i) stock-based compensation and (ii) other non-cash expenses.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Applied DNA Sciences </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="padding: 6pt; text-align: center; white-space: nowrap; width: 1%; vertical-align: middle"><IMG SRC="image_002.jpg" ALT=""></TD>
    <TD STYLE="text-align: justify; width: 99%; vertical-align: middle"><P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Applied DNA is a provider of molecular technologies that enable
supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and pre-clinical nucleic acid-based therapeutic
drug candidates.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Visit&nbsp;adnas.com&nbsp;for
more information. Follow us on&nbsp;<FONT STYLE="color: Blue"><U>Twitter</U></FONT>&nbsp;and&nbsp;<FONT STYLE="color: Blue"><U>LinkedIn</U></FONT>.
Join our <FONT STYLE="color: Blue"><U>mailing list</U></FONT>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">The Company&rsquo;s common stock is listed on NASDAQ
under ticker symbol &lsquo;APDN&rsquo;, and its publicly traded warrants are listed on OTC under ticker symbol &lsquo;APPDW&rsquo;.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Applied DNA is a member of the
Russell Microcap&reg; Index.</P>

</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The statements made by Applied DNA in this press release may
be &ldquo;forward-looking&rdquo; in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the
Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied
DNA&rsquo;s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks
and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected
due to the possibility of a failure to make timely payment on its outstanding secured convertible notes and resulting enforcement
by noteholders of remedies on collateral which includes substantially all of Applied DNA&rsquo;s assets, its history of net losses,
limited financial resources, limited market acceptance, the uncertainties inherent in research and development, future clinical
data and analysis, including whether any of Applied DNA&rsquo;s or its partners vaccine candidates will advance further in the
preclinical research or clinical trial process, including receiving clearance from the U.S. Food and Drug Administration or equivalent
foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the
U.S. FDA or equivalent foreign regulatory agencies, the unknown ability to manufacture the vaccine candidates in large quantities,
the fact that the safety and efficacy of the vaccine candidates has not yet been established, the unknown ability of the vaccine
candidates to generate revenue or profit for Applied DNA,&nbsp;the fact that there has never been a commercial drug product utilizing
PCR-produced DNA technology approved for therapeutic use, the unknown outcome of any applications or requests to U.S. FDA or equivalent
foreign regulatory agencies, disruptions in the supply of raw materials and supplies, and various other factors detailed from time
to time in Applied DNA&rsquo;s SEC reports and filings, including our Annual Report on Form 10-K filed on December 12, 2019, as
amended on December 16, 2019 and on January 27, 2020, and our subsequent quarterly reports on Form 10-Q filed on February 6, 2020,
May 14, 2020 and August 6, 2020, and other reports we file with the SEC, which are available at&nbsp;www.sec.gov. Applied DNA undertakes
no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date
hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><IMG SRC="image_001.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #0070C0"><B>Investor contact: </B></FONT>Sanjay
M. Hurry, 917.733.5573, Applied DNA Sciences, <FONT STYLE="color: #0070C0">sanjay.hurry@adnas.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #0070C0"><B>Web:</B></FONT> www.adnas.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #0070C0"><B>Twitter: </B></FONT>@APDN</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Financial Tables Follow</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="text-align: center; margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="text-align: center; page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B></B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>APPLIED DNA SCIENCES,
INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>CONDENSED CONSOLIDATED
BALANCE SHEETS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">June 30, 2020</TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">September&nbsp;30,&nbsp;2019</TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">(unaudited)</TD><TD STYLE="white-space: nowrap; text-align: center; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center">ASSETS</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Current assets:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font-size: 10pt; text-align: left">Cash and cash equivalents</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">10,924,968</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">558,988</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Accounts receivable, net of allowance of $26,131 at June 30, 2020 and $4,500 at September 30, 2019, respectively</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">231,192</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">839,951</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Inventories</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">444,640</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">142,629</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Prepaid expenses and other current assets</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">554,693</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">604,740</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Total current assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">12,155,493</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,146,308</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Property and equipment, net</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">750,532</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">226,221</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Other assets:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Deferred offering costs</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">109,698</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Deposits</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">95,027</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">62,351</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Goodwill</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">285,386</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">285,386</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Intangible assets, net</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">688,594</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">734,771</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total Assets</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">13,975,032</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">3,564,735</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center">LIABILITIES AND EQUITY (DEFICIT)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Current liabilities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Accounts payable and accrued liabilities (including related party of $27,097 at June 30, 2020)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">1,640,552</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">1,616,997</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Promissory notes payable-current portion</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">376,351</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Deferred revenue</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">431,214</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">628,993</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Total current liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,448,117</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,245,990</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Long term accrued liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">785,435</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">621,970</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Promissory notes payable-long term portion</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">470,438</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Secured convertible notes payable, related party. net of debt issuance costs</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,492,292</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,442,497</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Secured convertible notes payable, recorded at fair value</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">102,777</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total liabilities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5,196,282</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,413,234</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Commitments and contingencies</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Applied DNA Sciences, Inc. Stockholders&rsquo; Equity (Deficit) :</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of June 30, 2020 and September 30, 2019, respectively</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Series A Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- issued and outstanding as of June 30, 2020 and September 30, 2019, respectively</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Series B Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- issued and outstanding as of June 30, 2020 and September 30, 2019, respectively</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Common stock, par value $0.001 per share; 500,000,000 shares authorized; 4,968,197 and 1,207,993 shares issued and outstanding as of June 30, 2020 and September 30, 2019, respectively</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4,969</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,208</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Additional paid in capital</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">274,493,010</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">255,962,922</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Accumulated deficit</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(265,712,717</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(256,805,589</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Applied DNA Sciences, Inc. stockholders&rsquo; equity (deficit):</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">8,785,262</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(841,459</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Noncontrolling interest</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(6,512</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(7,040</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total equity (deficit)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">8,778,750</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(848,499</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total liabilities and equity (deficit)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">13,975,032</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">3,564,735</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>APPLIED DNA SCIENCES, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CONSOLIDATED STATEMENTS OF OPERATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Three Months Ended June 30,</TD><TD STYLE="white-space: nowrap; text-align: center; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Nine Months Ended June 30,</TD><TD STYLE="white-space: nowrap; text-align: center; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2020</TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2019</TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2020</TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2019</TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; font-size: 10pt">Revenues:</TD><TD STYLE="white-space: nowrap; font-size: 10pt; color: red; font-weight: bold">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt; color: red; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; color: red; font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; color: red; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; color: red; font-weight: bold">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt; color: red; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; color: red; font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; color: red; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; color: red; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: red; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: red; font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: red; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: red; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: red; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: red; font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: red; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; font-size: 10pt">Product</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">56,911</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">392,599</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">492,582</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">885,736</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">Service</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">374,605</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,660,858</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,124,926</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,830,511</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Total revenues</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">431,516</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,053,457</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,617,508</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3,716,247</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">Cost of revenues</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">154,804</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">270,883</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">566,417</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">557,508</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Operating expenses:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Selling, general and administrative</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,589,042</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,407,223</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">7,247,999</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">8,018,516</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Research and development</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">814,599</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">719,668</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,082,043</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,080,610</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Depreciation and amortization</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">61,865</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">87,315</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">203,469</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">320,039</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total operating expenses</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,465,506</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,214,206</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">9,533,511</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">10,419,165</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">LOSS FROM OPERATIONS</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(3,188,794</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1,431,632</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(8,482,420</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(7,260,426</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Other (expense) income:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Interest expense (including related parties interest of&nbsp;&nbsp;$26,267 and
    $75,577 for the three and six months ended June
    30, 2019, respectively)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(28,624</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(38,177</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(86,811</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(107,206</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Other expense, net</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(72,694</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(8,102</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(334,527</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(31,356</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Loss before provision for income taxes</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(3,290,112</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(1,477,911</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(8,903,758</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(7,398,988</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Provision for income taxes</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">NET LOSS</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(3,290,112</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(1,477,911</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(8,903,758</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(7,398,988</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Less: Net loss (income) attributable to noncontrolling interest</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">662</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(528</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">NET LOSS attributable to Applied DNA Sciences, Inc.</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(3,289,450</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1,477,911</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(8,904,286</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(7,398,988</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Deemed dividend related to warrant modifications</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,842</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">NET LOSS applicable to common stockholders</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(3,289,450</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(1,477,911</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(8,907,128</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(7,398,988</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Net loss per share applicable to common stockholders-basic and diluted</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(0.72</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(1.55</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(2.54</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(8.46</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">Weighted average shares outstanding-basic and diluted</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">4,577,997</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">952,835</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">3,512,149</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">874,272</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="text-align: center; margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="text-align: center; page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>APPLIED DNA SCIENCES, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CALCULATION AND RECONCILIATION OF ADJUSTED
EBITDA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B></B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Calculation and Reconciliation of
Consolidated Adjusted EBITDA:</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Three Month Period Ended</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">% &#8710;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; font-size: 10pt; text-align: left">Net Loss</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">(3,290,112</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">(1,477,911</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Interest expense (income), net</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">28,624</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">38,177</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Depreciation and amortization</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">61,865</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">87,315</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Stock based compensation expense (income)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">364,819</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">154,304</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Bad debt expense</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">21,880</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total non-cash items</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">477,188</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">279,796</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Consolidated Adjusted EBITDA (loss)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(2,812,924</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(1,198,115</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">135</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">%</TD></TR>

<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Nine Month Period Ended</TD><TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">June 30,</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2020</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2019</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">% &#8710;</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Net Loss</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">(8,903,758</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">(7,398,988</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Interest expense (income), net</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">86,811</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">107,206</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Depreciation and amortization</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">203,469</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">320,039</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Stock based compensation expense</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">797,577</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">911,642</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Bad debt expense</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">21,880</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(8,633</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total non-cash items</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,109,737</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,330,254</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Consolidated Adjusted EBITDA (loss)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(7,794,021</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(6,068,734</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">28</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">%</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 9; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  R 2P# 2(  A$! Q$!_\0
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M<\C!!R/4>M!(&>1G!."?3^E "T5\=Z'^V_\  _Q!^V=XS_8,TZ^\6/\ M ^
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MHW\C?[:&N?M[?$#Q9HOQ9_;UTW]H^36O%]I%X@\%Z]\=_!OCGP=X5CT[7/\
M3;6U^'.BZ]X?\/\ @CPWHJ&6:6RT/PCIMBMI&Y:6SAD:>9J<)KEO"7-*2BH\
ME7FL[^]9T$^56U?)U7F-IJ$9R]WF;26LHW5VX^V2CAG-;^S6(E4:?,J;C=K^
MQW]JC_@Z _8T^$DFJZ)^S5X&\<_M5^([#SK=O$,<DWPA^$JW.8PK1^,/%6@Z
MCXKU=0PFQ<:3X!GTJ]^S+%8ZRRW"7$?,_P#!'O\ X*^_MY_\%$OVN-=\-?$#
MX >!=)_9:7X?>)]<G\;?#WP;XYL]&^&WBO0[W1O^$7TNY^*'B/5K_1?&&H^*
MXK^;3YO#4-KI^LM''+XALK#3-(TS4+-/RF_X);?&[_@WT\!MX;B_:$^"GQ+T
MOXVV26LEU\1OVO=+T3X[?!U-6>!B)_"VG^ -,B\(>&K-91,^EW7CCX*Z)JFC
M@P32>)-8-O)K<W]>G[,OB^;XD>.O$WCWX3_&GX0?%+]F*6S>W^'MK\'/%?A+
MQ)X/T+3W_LX:'H^GZ7X-$UKHNI:=&FH'7I+Q[%K*XB:,'6(]9GA\)9\RNT[J
M2;3BU)2T=FTI0@VNND7IM=Z U)6?*^5_:5G':]KQE/7I:[=^A]]T53%P2NX'
M<,<% &QSCG&1UR.O4$=:42N0#GJ >J#\P02#ZCUJ9581DX2<D[)_!-W3ZJ,%
M4J)><J4(WTYG+W3-SBM'TT[:]O>]G^;].I;HK.DNVB=58KAE)RV.Q )R"H &
M1U!Y(^E6TD+,HZAL_,,%> 3UX_0?I352#VENTEH[N_\ =_B1UTO4ITUUO:TF
MXR4K\OO6^+=<M^[DHQE_W#J5?ONE-1115E'Y9?\ !0[_ (*R?LZ_\$\[_P #
M>!O&6B^/_B[\>/BC"+OX>? ;X1:/;ZWXYUK36O)M,BUO4I;V>WT_1=&O=4MY
M=+TK#WNOZ]J,%U!X>T/5%L=2DM.)_8#_ ."R'[/W[;WQ+\0?L_:A\/\ XL?L
MT?M.>&M*O-=NO@5\=M!?1/$6MZ)96UK>ZEJ/AC4PL45Y<Z;:W$=WJ'AW7+'P
M[XGCTY;C5[+0[G1=/U.^L_R\^,OQ8^&W[ G_  </_$3]H[]LV*?PQ\&/VE?V
M9O#/A/\ 9Q^-VJ:+>:UX6^'/B+2_#'PV\)^)-+FN=-L[V[T6=K_P3X]AU?4+
M2-K[PYIWQ!MKG44M_#'B_4=1M/&_VJ?VYOV7OVK_ /@N'_P2EU/]E#QAIOCW
M5/A=XZG\%?$KXQ>&+/4+?2/$5EX[?5+72O &F:QJ5E9W/B.PT'2+OQ9<7VHV
MR7.B(/'L]CINH7,[:@EH ?LG^WA_P6@^ '[&'Q<M/V;?#/PS^+_[4_[4%UI]
MGK.J?!+X$:%'JVK>$=,U'2[/6=*;QAJ<BR/:ZEK'A^ZA\06.@Z%I/B?7K;P]
M)#KVO66AZ#?Z7?WGK'_!/'_@JO\ LZ_\%$$\;>&? &F^./AA\;OA:\Z?$WX
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M-RD<+D$8S7MW_!:KPW\2_@W_ ,%B_@7^T1XE_:2\5_L>_"[XC_!/3/ GPO\
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M6_;Q)H&I6%H!))/3LNMRW_P39_:[^'/[<?\ P7\^-_[1?POT?QGX;\.>*?\
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M #_/@_X)9?!7]E"\T:]^//Q%_P""A.B?LB_'7X=^.[_2_ /AFY^">K_$?5=
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M] M5L="T;2M$L5DDF6STC3[33;599=GFRK;V4,,(DE\N/S7"!I B!RP48U:
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MP6('X4HBC#%@O) !.3R!TXSCCMZ?C41Q.-II1AC,3%?7/KR]EBL32C3Q^_\
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LW:]U*2YN2TTK&4F1RW5P_P"K_P"!R_\ HUZ** ):*** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "I *H# 2(  A$! Q$!_\0
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MZ;X5^(-ZLP@V?!3]H-M+^%/CF>_EF9(#I6A>+=2\">*[TWLB6=G;>'#JDUQ
MEJTM87[+/B'PKX1^+WC7X2_ B;3_ !S^S#XF\-Z?\8O!NN^"=2M]:\(_!/QQ
MXCOI3XN^$SM9W#P>'_#7C*-(?B5X)\/Q[+[0==U'QO:7-I:66I>%+<?8_P <
M+[X)P?"[Q9IO[0%UX A^$GB+2+S1/&-G\1[K28O".L:-?1%;S3+^/69$LKR.
MXA#$6X\R5V57B0R(A77,,'4H9C'!8.C7QL\5*D\%A,)1K8K,6L54:H4JN!PU
M.IB(U(*4:=50I2E[2$G"E*$Z=^7 9I2JY;]<QLX82-"#6)Q56<88'FI)1JSC
MBZDH4TG*,Y\C?-"_(Y2E"3?R+\-=>\/W7_!3/XSCX4ZMIGB3P]XC_94^'Q^/
M\OA>YAU'0O"_Q:\ ?$[Q)IGPD@UV^M);C3++QKXJ^'/B_P :P7.F6T\FLS^'
M_ VCR^((-/M;+PTEUZ=\<O@MXD^(/[5'[+?Q 3PSH_B'X;>&/AM^U7\+OC#:
MZO/9&VG\-?&;PS\-)M'TJ]T>\#G6M,U76?A[)I]_''#<"UM99O-B-O=W&[\N
M/&G_  6M_P"">/[+^B'X=?LJ?#.?X@:;IFZ.WT[X1>";#X7?"Z*YA@2W$DFO
MZM8:5)J]RRP6]LVK:7X9UT2(DCI?2J#YGY[_ !!_X.(?VF]:GE_X5M\%_@]X
M L'D*6[^(9/$?CW5(%RV))&CN/#UK,_EL!YG]G6T>0R["&-?IW#W@7XG<1X?
MZWA>'7E^&ND\1GN*I9-!-Z*/L,8EF+<G[L>7+W'F3YI0C:;^%SOQE\/LBJ2H
M5\WK8_$IJU#*,)/,')7:DXU(5:=&T+7D_:;--7U2_?3]@']ESXU?LM^)/VJM
M%^)6O:#XL^'OB7XB^!#^SSXEM-;U/5?&M]\&O!OP]TGPCX:TWXI0ZM86LD/C
M'PCIFGZ?X/DU5;_5KOQ5IWA^SU[4;YM:O[YGB\3_ +$7B#XU?'/X]?&7XN_$
MGXB>";CQ!I.E?!SX'V?P3^,GC3P=-HGP4L=$35]?D\;V>FV>C:)>Z[XV^(^L
M^(]>U;0;_3M=MM+\/VF@VR7]]J4$4D/\Q=]_P74_X*+75Q));>/?AEI2;R8[
M:T^$>ARVQ!P2NZ[N;N=$W$D>9<R,.Q484=+X;_X+X?\ !0#19$.KW/P7\90@
M;I(-6^'EQI"@C (%UX?U?3IHR0" \5E<R(""L,A %?7U/HN^*,:#K48\.8R2
M5Y4L+G<93CV4G5PE&*YG=1=VGRN]M+_*T_I'>'<JWLJT>(,(FTHU,3D\H1GW
MY%#$56^73F3Y6DU:]]/ZT_V(?"?Q*\ _LF_L_P#@+XNZ5=:/\1OA[\/-'^'_
M (AL[W4;?6+L)X*N)O"NE:A+J5N\R7)UO0='TO5C,LA>5;Y1<)%+$T:\+^V/
MK=_K^DV7P\\):GK5_P")?"AT3XX_$/X;>&/$&L>"O$WQ#^!WA+5Y]-\7>']
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M$W[.]GJ7B A]2M84>RNG'EW;W5KJ4]K;2I(3N!-A%$CJ 5F;+DEF-<A^S/\
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M1M1-PJ6"VN[E)'MK:^GB@<I<7<&F7]W9Q2*/FA\ZW@B0%0,DM("%&XX (/\
M1_\ &O\ :&_9/_; \4?!W_@EK^SA\']=\"_#_P#X:;\$Z5JWQ-LDT31[#6M$
M\&:WJMU\1;K3;.SGBU^2]U;2M.U6.T\0:S(;J>1K60V[H;94^^/VM_VL[G_@
MG?\ %;]GK]FS]G']CKPUXO\ A'K/A[P_KGQ-U/1_ OBJX72_"VH^,V\$VND^
M'-0\*Z1>:9/XKTZVTO4M9U>?Q3-J=S=17.CRM9+;7K7,WIU_&?-L/_J_D>'\
M-<53X@S;!YGF-')<PXDPF K_ .J.7P^LX/-L9G.)QM*%#,\9-)RPF(KTL34P
MO+AG1<:U-2XL+X1X6<<TQO\ KE[3(LBJX7 5<]IY-C,TB\XQ,E0G@9Y5A\'B
M:U:EA,4Y4IX_ZO*A*%-UU6=-^U/XP(V$FYT<R1 E6DBPZ!E)+*)U=H(G4 ED
ME#L(U9MN5)%F&WNKI#/9V5]=01AO,N+:RO[NV)8!8WCEBM4CDB1@P>>.4VRR
M!HV)*$#^C_\ X+/?LG_LZ?##]JC]D[XK:E;:?\-/A1\=?%VI^&_VA9/#6G&T
MTQM,\#:AX=UN]\4VVDZ-;?N=0U3PKKE_::B--@"W3Q07*0>8=]?3&L?\%3?A
MGIOQR^ '[-?_  3F^ G@#XX_!O6;KPKX>^(UQX8\">,](U+PQ9ZCK/\ 81T_
M1+.WT+3H89/#^AQ+X@USQ#XOMKZS>&*87%[DR3#I_P"(PYIF^0<,YUPCP-CL
MY?$W#^>9GG-2OF4,FRSA.KDRS7#8K!?VOF6%>55,<X8!XC"X=UUC*\E3G0HW
MJ<\>1^%N"RK-^*,IX@XMIY7_ *NYK@,!EJ_LRICL=Q.LSPF$Q>&QN%P=&G6Q
M<,%2JXWV=>=&A4PT.1T)8B,J7(?RI?#/1]+\5_$7X>^'=2\VZT;Q!X\\&>'=
M82RNE2:2TU7Q%9Z;JEM%<03!HWGMI)HS);3QW-J[$PRPSQAD_:S_ (++?L$_
MLU_L8>&_@%J'P!\(^(/#VH^/?$'CZP\5MJWBWQ/XFM[JUT+3O#5SIZ6Z:S/?
M0V7V274;MO,@>"6Y60"\EG6.,I] _P#!:#X#_#+X;?M8?L4?$OP'X5T;PIKG
MQ.\?V6E>,(M#TVTTFSUZ[\)^//!']F:Y?6UC'#;1ZC)9ZY?17$UM9QRW'V=6
M9CY7R^F?\'(97_A#/V3?,W#RO%?Q0,L@ 0@'1_!99E=QM&0"-Q.TD$9)XKP:
M/B/F'&''G@)FV5SS+)LEXRPO%=7-.'ZF:X>K@JU?*L+B\!&.+P^$PF"H5XT\
M7@YU:/UA5KUI*K24)J2E[&,X H<-<&^-678O!X?.,TX;?#]++<YE"G.4,-B\
M;EF95*^';<I4[X.O-553E+FH4JD7)TZ<Y1_FV^"GCI/"OBG[)?,!I'B<+8W,
MLB0FV@E1X9K>:9Y5(B13 \+&-D+O,B%B2*['6?@-?WGC^>&SFCM_ =PZZD^N
M-/&1!:S3M/=:;;AR[_:6EN'"3S&1(K9Y&8AHX=F'X"^%FGW&E_\ "<>/[@Z9
MX7M0E\NG.Q@>_M X,%S>HP258)9D4006BI<74K1S0F2*&;/L/A[QWX9^*]OX
MB\!6\=[H$<EC-;Z*T<^R[NK6*-A'+$ZD2;T98BUJ"9GMB[3H57C^K\LI1J9?
M@HYDTJE.E3KX1*4/:5Z]2G2ER5%*2E)<R2BFN5J4M>I_G'QQQ%C,%QIQ+Q+X
M8_VIBL-7RG$9)XAYKA\FPF+R>C&ICUA*..RZEB8^SQ_$.38>I4=*--8C#JA&
M.(K5J52C2MY-\9?'.E7MKI_P]\)M$_A_PZR)=SVI$HNKRV;:;&"4[WN4C/[Z
M:=7?<YD*N8B,>!<%LL206&2#C(R22IR,9!XVXP>5[&M37=$U#PSJMWHVIP-:
MWMA/Y>&#)YR2QK)!=1%@AVWMK)%<J8_D,<J[/W9&7-X<UQ-)776T;5$T5BNW
M5VL)%LV:1BD:K<D" ([*T:2!LL48*"X(KSL5*M7Q6(]NIN2E*%:,%*?L:,9V
M<(\D9<E.G'F]FFHPCRI1V1^W\)Y7D7#7#N3X'+<SI9GE>98C%8M9QC:F&I8C
M.<SQ.'7M,:Y5,1!8JOCL16C]:=*>*;E.I"6B5_J[]AS]LGQQ^Q)\?-%^+/AI
MKW5?"&HO:Z'\5_!$$Q$7C#P']K>YU"&TM6*PCQ'HD<MSJGA>=?(D2_A2P:7[
M!<30/_=?\0;SPC\>O@_X:\<^&?BI\1+#X/ZSX?M/B%J>H_! WLGBCXD^!9=)
M;4;?0-)O/#>BZUX^LH=34L-0L_ ']D^-9%6?3+?4K"24,G^<02A!:7)C&#(J
M*7=XB0LR1J%+>8T)D6,@':S*>H.?ZO\ _@WN_:KN?$?A#XB_L@^,-262^^&Z
M/X^^$\EU<Q"2;P-JVH/IOB_P]:GS?-N(O"VLOIE_;&)6067B#S?EBB5C_(7T
MEO#V&,RO#^(N54'+/>'U]7XBI4(4Z7M>%?:T\)@,8J_LFZF*P,\7&NVG4K4H
M7J3<8T(U*7]B> ''5:AF>)X%S:K.61YCA:-/A^I6K3<X9]0A/$U\M49SCRY?
M-8?V5&DDJ51J-*ESRJ<DOTV^$WP9U[Q;XH^$WBKPY\(M#_91^"?PF\17/C3P
M1X6EL[*/X[?$.^U#PY>Z&T/Q"EL+V\L?!/A?7;'71J'BKPCKNIZ_\0O$&HZ5
MH[:_J&C7.GWU@?TIC2-[9%<LZ20J9$F!8N'7+B53O#;@Q5UR5*GR\% !7R9\
M1?BU\6KSX@W_ ,)?V??AWX:\2>(_#6FZ)J'CKQ[\2?$6H>'OA[X(A\01O>Z5
MI<.F>&;+4/&'C'7]0LUEOGL+--+T:TMH?+U+7[2>>*"71^ /Q3\;^-=9^*?P
M[^(MS\/=1\<?!WQ#H>A:_K_PGDUR'P1?R>(-)76K6T?3?$=WKFLZ)XET*(O;
MZWX?O/$.I):I<6=W(T"SVZK_ !9F4,SQE.EC:DJ,J='!4JM*A?GQ?U/$UN>E
MC,=.HZF(J5\56J^Y5KU(SJ0G!TJ,:3B?UIE,\OPTG@Z,ZKG4Q$X8ITXU'0I9
ME#2MA</*G!T84*-.-G3IR<(55*,Y*KS)^Z>#7-C-JGA::5V?P]=_\2XNQ+W'
MAZ_1KK2I!_$T5C++?Z$'E):=]'^TDL)$-=]7GNKJ-)\5^%M8"B.WU..]\)W[
MI&^Y4GADU70W&Q2JJM]875A&7.#-JEO!&GF3QANWW3?PDLO8[,Y'8Y'7(YS7
MBZ-1E?64>:2_EE=IQMTVNEV=['T2WE'I&7*GO=633;[ZZ^AP_BNYCN_%/@7P
M[N)>:[U?Q/+%@E9K?PU;P6L<;_PD?VIKFFSJ#D_Z,SCA#5CQOXX\)_#GPQKG
MC3QIKMEX=\,Z!8RZEJVK:C(PM[.RM\1O)Y<2RW-S(SF)(;:TAGNKF>6*"W@E
MGEC1JJ6UO=_$R:Z?YKGP[X,MXX1@E8AXFUB_>XYSUD'AV%>G.P'C&T\I\>/A
M;>?&3X:^(_A_IWB^_P#A_J>K2Z'?:-XTTK1M.U_4?"NM>'M9L=>TG5M/TK6H
MI='O+NRU"P@DC2_BDAW#YXV&U15)866)P?UV<J6$^M4O;U8\RE1IM34ZJE%3
ME%Q3=I*ABFFTUAJK2Y<,7[;ZIB?JU-U<1["?L::LN>I[KC%N4H1BG9WE*48K
MJU>YY1H'[6'[-GQ;U6Q^&DWB$0ZUXQ\^PTGP9\5/ GBOP+_PFA"J7TW1=/\
MB-X:T?3/%=P(2LG]F6<UW>/;;I([>813B+\S/^"N:_#W]CW]AWXI:5\&]'/P
M_P!5_:>\1>'?A*?#_AS5M6L/#EEH^H7%[XA\=WWAOP@VH?\ "/\ A6[O_!^C
M:GH]W>:%IT"M<:U;FXA#%9T^Q?BQ\$OVW/%/AK2_!VI?$']G+XV>%+#Q%X>\
M3ZS;:SX$\8_!'Q]XA/A;5+77-.LM.\467B#XN>#O#&IOJ=A#(_B"P\&V]Q'
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M$UO5;RWGTS1[K2+6#3)=(\1:(D,.VY$\XN([KS&C\N(0B61S_<WC/PSGG&W
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MJ[O-2)NC;KK-EH4>OWNDQ:T+%?"EQXHTS2[A-6O-!@MB((HWMGD68[3\5?\
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MPUIGP]\:Z5J7A70CXC3Q2VI,LWAW1M/FU"]7P\-NJ&[A\RY8BYNN%_X)5_\
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M=*ESU7?V;@_VHM8;:TA@M+2*.*VM$CM;6&)=L4-O:QB*.*,8PJ1QQJBIP,
M<"M%"Q5& )4JI SC@@8.#T]3QG^55K=.!GD*Q.", #&T@#/RJ!V.<$D9Z5=7
M"HO8!1^0%?YMPP[2I*K4J3JVQ%:M4YKN57$XJ>(G&3=VW>K?5N6C<G)MM_W\
MDX2J4]/9P<(4(QLHQI1I0222Z\T;.UDDDDE8XSQS#-?>%]2TZW?9-JC:=IL8
M9U3>NHZE:6TD89V5=TEN\RX)&<X[UT@DNX@(HK5&CC_=QL9HP61/E0X,@(RH
M!P0,>@KDM>#:GXG\)Z+&6,5K>S>)M2520!9:3;7-KI2,0 "9];N+6Z1LD".Q
MEC*YE1T[,6BXY))[G<W)[G\:Z_\ )+[AMW))@3M/("Y;("DAMR '+(^, MR!
MG&>U<3X1+Z2^L>$F*1#1+J6XT1'Y7_A'-0DEETJVC.\;H=)8G2TVA?)M+>T@
MDW2AIY.]ZUP?BR"33+BR\6V41:71(I+;4[:)27U#PU. ^I084\R:=*EKK%G*
MXS ;&ZMXV U.<,".ZQN7!/5<$CCJ.2 >GXU5DM8BC!BS!@J,#MP5)4$$;<?,
M,@X ."=I4@$36\T5Q;P7$,J303PQ313H04FBE17CE0C@K(C!U(."""*X7XH_
M%#X=_!GP'X@^)GQ6\:>'?A]X \+6T%WXA\7^*M3@TG0])M[F\M[&W:YO;A@@
MFNKVZMK.PMT#S7M]<6UI;QRS3QHR<8N]XIWBX-V5W"6KCS6YE%NS:4HJZ3W2
M:32?*WO"2G%]8S2:4E:VJ3=M]]NWY^_M[_ >3Q/?_"[QEX;TZZW^(+7XO_L^
M_$74-.AD,]IX4_:!^'M_8^&_$EZ+,P.L.B?'3PM\)=0N+M%;[&;NZU$QH1/.
MOS9J/]H?M7> O#?PI^-GP%O_ -HWX9?%SQ+\&=5GU;[3HNA:W^SCX'^('P.T
MM-5\>Z)XDE:RO;:R^'GQF^'WQ'\^9+YO$23:I'IHGU<11VB_M59ZQI/B31M-
MUO0[W3]:T+6+*VU33=3MI4N=/O+&XM_M-K>VUQ"S1RPRDQ2P/'@H=_ ,>U/Y
MG?\ @M7XZ_:U_9Q\$Z%\,?@EX?LOA9^Q?XHTUM*UOQQ\-8[[_A+M1\2>(=4U
MS5]=^'OCGQ)<B]N?!7AG5[_5]4U#0FTV.T76[G4=0T^34(5C:WC_ %'P[GC.
M)\]R+A6GB<!E>,HU;99G>98W$8!X=3J7@\'B<+.6+Q^/PTY+ZIE&&C/'8UTH
M4ZC_ +-]O;\JX_C0X<R[..(*F$QN98#$TU+,,HRW!1S.>*2IN%2.,PM52IY?
M@J[BY8G.E)?48R=549.,9+Z,^ 'P%^%_[(7A'5[G]@G0O"GQ^M]2T7X[6OQF
M_:L3QIX4\;_$7X=^/OA_X/UC6/A_X*&@:=;3Z=;Z#J/B#1_['U2*UMEMHWG@
M.H6>MWFH1W@X#Q;XMU^\US7_ !%X%N;K6O$L'B3QSJ'PV:[G>[OM4O-0\*^"
MOV^OV:-($]S))'+8:H+OXU_#G3(#-<I;R:IK.B_-:6MK;0?S'_LW_M3?'']D
MKQTOCWX$^-+KP?J4IMK76]#N5FO?!WC;3TDFF&C^*/#-Y?36.OP123227%U#
M))KVAS3.]O=*[KC]^OA7_P %,OV*?VC=2T#6_CE!JW[&_P ==.\7_ GQ8WCC
MP]I^K>,_@]KEQ\!M8U*_\-:<-/BM[V3PG8ZSH/B3Q3X)O3JF@V%]8>'-8F@?
MQ#-!"T<G[UQCX1\<<-YI5SAX?,^/\#5I^SQ'$\<-.IG]?'QIN-6CB>&Z4<?5
M^ITZL:D)?ZLT\90PV"I0IXW(:5.&+S+$_C7#GB-POQ'E%')<-&EP9*C5IRI9
M+7JX6ID\:2DO9U</Q-)X.C7KU%[)?5>(JV#^O3E*.6UY0K86I \5:G\-I='\
M3Z/J.H7NE_ >SL_!_A;Q%XCTM[NVU3PY^QA^U)?R?$C]C/\ :)T&XMG^TVVI
M?L8_'>[\3^!8-7M9(]8L] UC5[75IV:/3IH\B#XJ?$GX4^(/'WB_Q!XXO_@O
MXM_X6#X?^%'[:NO>'+:"/0_@K^U)IMN;/]GG]O*T\.207&A:E\#?VCO#JPZ+
M\9+2XLW\.7T.IP/JVG27<=A=:1]"Z+^SY^SKJ4OP[O\ 2/VTOV3O%'P7TW1/
MVC_@7\2=,;XL^$K,^(?V.?C-K3>.OAOX&DFDUN\:/QC\%?&=[JU]X;U"^DL(
MK6U9X(6M7#(/G?7OVHOV%OV.=$\+ZM??%6S_ &]OVI?#7P2D_9OU^7P-"^F?
M!;Q]X$\/ZV-8\%R_&O[0NN^%/$VO^"Y-/TO3=(U2#4?$6O7$5E:MIFFVL[F>
MOG,OPM#,J57*\FX>SS.LPG1=+$Y;B^%\TR_"5JC<5!8K,LZR/*\KRG!>TIK%
MX_-<?BUALOPV,RG$SYJ-+'>W]+'1KY8GBLUSW+\CPOO+#X["8C)I8JG0E!JL
MZ&'R3B#,LVQV,5+EPN$P6!PDZ^)QF#S>G&2J3PZA]?Z5^S/IOCW3M4_;A^)?
M[!]M<_M[_#_2_&%E9? :W\9^'-(^%OQ_^(O@K4M-T6+X\^%O#UYJ+G6=(U,2
M-KOAB;6+F6*ZT">*XU$:QXC3POJZ?(GCSXJ^/?$^H>(-9^,6KW'QMF^$/Q3\
M-6?BOPGIL#P>"OVF?^"CVM(;'X/_ +)_PVTEX[6&7X ?LEWACU7Q<D4R0:WX
MG\/7.O>,CK&IW45[:_C#\3/V]/VI_BE^T+I'[3>J?$[4_"?Q-\+7"'P)9>#S
M)HWAGX<>'H9/.L_!^@>'LZG;#PY(K+9:_:Z[=7%QXNFBECUNWBE#65M^P'PB
M_P""E?[)W[25[X"\2?M36<G[,O[3?PR\/?$FP^&GQN\,:/K&O_ VP^(_Q.T4
M:%KGQ8F^'=J9;6U\?6#>1J4%UJUOK5UH-Q%Y]_XF@M(PJ_:9CX<\=\*0P.;9
MQE./XNP,LOI-X/(8SS?,N%*-.%94N'<JQ^:UJF:_V#2CB_88?%9?1I9WAZF(
MS#&YA#%X6GP5[/Y_ <:<)<2/$99@,1A<@G3Q4Z$*F*Q2P> XC5-1_P"%VM++
ML+_9>(S><X5\3F&79A5KY/"G'+,%@*U'%RXM<>TTU==LIKCP'HGBZ+Q3\0Y/
MBMJW[/%E\5HV22R^(G[;OQTL?[=_;S_:)TRZ:&&UD\,_LD_ !/'/PD^'TTMN
M^G^'C8IHEJ)IKC3KE/3M-U>'QA86MEX6671(OBEI>AQ>%;.+=!<^$/"/[2/C
MWP[^RE\![6"\B!NX;?P[^Q]\*/'OC:YNT9-1MX_%>N7_ !/,NWG=,^#W[(WA
MWPCX>@\)?\%)OV9K+P3\.?V5_&_P9^$VOZCXT\/W?CBU^*/QWUE[K]I?]H37
M-'A\26<VM>,?&'AC4/$GAW0=.LK7S?#-K=M<74YDLE>+E?B/_P %#/\ @GM^
MS/JOB#6O@5#XF_:U^)D'B/X>^(_ -P$OO"?P9^&]Y\'_ (-P_"#X?Z?9>(67
M3YM:TG1/#DNOZA]D@M_$5Q>ZEXGU&[MULT+WL'PSRW,>(\?/!<,Y1G6>XJLE
M&4Z?#N8Y7A*4YSJ15+-JV?4H9/E.(A%0Q&/J0G/#898FC@Z$:E#+TW]76Q6$
MRC!TL7G>;9+@L+AKJE##<0Y7F%:C[-0?)@\-P_)YUG-:D[894)SHU,1.A/%5
M8TJV/E"/W)\7HOAY^T'\)/,_;2\-_#S0?V)KCX=>+_&.D?M"^-?$I\(?%/X>
M?$#4OBWXVT?X?>&/A>J6DNJ^5I'PTL/"TI=K1IM1N9K6&[A\2^?J=C5[X0_"
MG0OV8-.T[X0_LU_#ZT^&W[/-WJGP"\70_M9:9XNTGQ1XN_: M&\0:UXN^,FH
MZKXBTR!DTG2]/^'_ (#N;;68;P16EMI_B02>&K;3K9K5(OY._P!JK]L_X^_M
MB^+(?$?QH\7K/I>D-<_\(;\//#4+:%\._!-C<M""^A^&([_4#?7"K;06TWB*
M[NKR_+PM+'>,")#[I^PS_P %"?VA?V8[NW^#GAS0#\>O@Y\0M0'AC5/V=-;6
M[UL:P_BVT?0]1T7X7WJO<7NA:QJMM=""YT;[.VDZO-/"MW!^^=Z^QQO@/QG@
M>#*\HYMAX8MUY9AB> ?[468951I4Z<Z]3$PQF%JQP>(QN$I4JTOK^8+#<.YC
M6IPK951D_8U*GRN#\8.%\7Q;A8XC*,5*E1H1P='C9Y;4R_-IUKJC2PLL)B8U
M,50PU>K.C3E@L!#%Y[@:<Y4\VKTW&NX?M)X:^'.I_'Z\\)>%M<L;BW?XX6O@
M[PAKEEL\G[!I?[2?CS7?VS?VKRL4*KNDM_@SHOP1^&UQ?R9NK'^T+;36GGGN
MI2?Z,? _@K1_!UMJT.E6PMWUC6]2\0ZK((XXGN]7U:=YKEY F5\JS@6UTNQC
MCVPQ65A L:GYI9/%_@G\(_"&AZ=X>\??\*VNO 7CC6K"^\27WAS5]8L]<O/
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MOAIXY^.GAW3K _&?3OAQJ.D?8/!WBW686U,^';C1=+U#4;W2++2X'?2M*O\
M594GU9;$WT@4SM''\N?M6?\ !*_]D;]L$W/B'QKX(?P=\0[U'8?%+X7S67AK
MQ/>32*'2?7<Z=?Z'XIB,CC(UW3-1G<*RKJ43$,O];>&WTG<7E6'IY+XA4,;F
M6&I4J-/"\992XRX@I0I484Z.&QF4-PPU6E%TJ<:^849O%J//7C1J58I2_F3C
M[Z/&%S.I4S7@JO2P'MYUJV)R/,TW%U*TZE6I]5GS3C3O.I-0A4J<L;P49J*?
M+_G^R6%E)+YLMC:2RY#B4VT#E@QR'5P3N&.XSM/RM@\5<52 JG;M5=JJJ*@5
M01@ +P><\]1QGM7[V_';_@WV_:B\ R7=[\$?B!X(^.^BJKR1:=J$:_#/QLAA
M!\J"?3KZ[U/PO=R^6S1I<V6M:>L[+O>PB4@I^7GQ"_89_;+^%<EPOC?]EWXW
M:;;VCF*?5=+\ ZWXKT0,,Y:+6/"5OK=A<195L/'.=P4LH*D$_P!6\/\ BCX?
M\48>C5R7BS+\34E&,J]#-<=##9I3FU>,?98WZI.3YFU-4_:M--;IV_FC-_#W
MC3ARI6H9KPU6ITHR2HXK#8.==3C>WNU<*L3349))/GE!N-K1>B/EC ]!2$#'
M(!'&01P0#T/^SR<^G/TKHKSP=XWTZ1H=1\"^.]/G0X:"_P# WBVQG5O[LD%Y
MI$$T1(PP$L:94AQE"K'H_#OP=^-'C"XAM/"/P7^+_BBZN&5(8M!^&'CG43([
MG"(ACT!0[,Q  0G)R 3QGZR6:Y1"DZU3-\GITHJ[G5S?*J2MOHJN84Y2MN^2
M,K7NTKJ_S2R_,75C1679BZLGRJ']G8]MO16N\'R]MY)?<><".+)9884.,NZ
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M3]G+QG\2M3^$^J^+/C/::[IUU=?$#XC7G@Z'Q9X7/@[QY+\)[CQCJW_"L/\
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3Z!U% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
